Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04392622 · ClinicalTrials.gov registry record · Phase 1

d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC

A Phase 1 study of Xerostomia, sponsored by Stanford University.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT04392622 is a Phase 1 study of Xerostomia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 40 participants, below the 92-participant average among 13 other Xerostomia trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04392622, a Phase 1 study of Xerostomia, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.

Conditions Studied

Interventions

  • DRUG Cisplatin
  • DRUG D-Limonene Gelcaps
  • RADIATION Intensity modulated radiotherapy (IMRT)
  • OTHER Xerostomia questionnaire

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-02-15
Est. Completion 2028-05-15
Phase Phase 1

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT04392622

The ClinicalTrials.gov registry entry for NCT04392622 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 13 other Xerostomia trials with a reported enrollment target (57% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Xerostomia appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.

NCT04392622 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04392622 about?

NCT04392622 is a clinical study titled "d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC". This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.

What is the current status of trial NCT04392622?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-02-15. Estimated completion is 2028-05-15.

What conditions does trial NCT04392622 study?

This clinical trial studies the following conditions: Xerostomia.

What interventions are being tested in trial NCT04392622?

The interventions under investigation include: Cisplatin (DRUG), D-Limonene Gelcaps (DRUG), Intensity modulated radiotherapy (IMRT) (RADIATION), Xerostomia questionnaire (OTHER).

Who is sponsoring clinical trial NCT04392622?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04392622 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Xerostomia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.